Novel 2-[4-(aminoalkoxy) phenyl]-4 (3H)-quinazolinone derivatives were identified as potent human H3 receptor inverse agonists. After systematic modification of lead 5a, the potent and selective analog 5r was identified. Elimination of hERG K+ channel and human α1A- adrenoceptor activities is the main focus of the present study.